Description

Afanat 20 mg contains Afatinib, a second-generation tyrosine kinase inhibitor (TKI) that targets the ErbB family of receptors, including EGFR (ErbB1), HER2 (ErbB2), and ErbB4. It is widely used in the treatment of EGFR-mutated lung cancer.

🔬 Mechanism of Action

Afatinib irreversibly binds to and inhibits the tyrosine kinase activity of EGFR and related receptors. As a result, it:

• Blocks cancer cell signaling pathways
• Inhibits tumor cell proliferation
• Promotes apoptosis (programmed cell death)

This irreversible inhibition provides sustained suppression of tumor growth signals.

💊 Indications

Afanat 20 mg is indicated for:

• First-line treatment of EGFR mutation-positive metastatic non-small cell lung cancer (NSCLC)
• Squamous cell carcinoma of the lung after progression on platinum-based chemotherapy

📌 Key Features

• Strength: 20 mg
• Dosage Form: Oral tablet
• Therapeutic Class: Irreversible EGFR Tyrosine Kinase Inhibitor
• Administration: Taken orally once daily on an empty stomach
• Monitoring: Liver function tests, skin reactions, and gastrointestinal symptoms monitoring required

⚕️ Benefits

• Targeted therapy for EGFR-mutated lung cancer
• Irreversible inhibition of tumor growth pathways
• Improves progression-free survival
• Oral administration for patient convenience

⚠️ Precautions

• Common side effects include diarrhea, rash, stomatitis, and nail changes
• Risk of interstitial lung disease (rare but serious)
• Dose adjustments may be required based on tolerance
• Regular monitoring essential during treatment
• Use strictly under oncologist supervision

Afanat 20 mg (Afatinib Tablets) offers an effective targeted treatment option for EGFR mutation-positive lung cancer, helping improve disease control and patient outcomes when used under expert oncology care.